Cargando…

Advances in Treatment of Dyslipidemia

Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dybiec, Jill, Baran, Wiktoria, Dąbek, Bartłomiej, Fularski, Piotr, Młynarska, Ewelina, Radzioch, Ewa, Rysz, Jacek, Franczyk, Beata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488025/ https://www.ncbi.nlm.nih.gov/pubmed/37686091 http://dx.doi.org/10.3390/ijms241713288

Ejemplares similares

Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
por: Dąbek, Bartłomiej, et al.
Publicado: (2023)

Advances in the Pathogenesis and Treatment of Resistant Hypertension
por: Dybiec, Jill, et al.
Publicado: (2023)

Chronic Kidney Disease as a Comorbidity in Heart Failure
por: Szlagor, Magdalena, et al.
Publicado: (2023)

Structural and Functional Changes in Aging Kidneys
por: Dybiec, Jill, et al.
Publicado: (2022)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

New Insights into the Nephroprotective Potential of Lercanidipine
por: Hajdys, Joanna, et al.
Publicado: (2023)

Statins in Chronic Kidney Disease—Effects on Atherosclerosis and Cellular Senescence
por: Fularski, Piotr, et al.
Publicado: (2023)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Cellular Mechanisms of Coronary Artery Spasm
por: Franczyk, Beata, et al.
Publicado: (2022)

Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
por: Wronka, Magdalena, et al.
Publicado: (2022)

Novel Insights into the Molecular Mechanisms of Atherosclerosis
por: Wojtasińska, Armanda, et al.
Publicado: (2023)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
por: Wronka, Magdalena, et al.
Publicado: (2023)

Acute Kidney Injury in COVID-19
por: Głowacka, Marta, et al.
Publicado: (2021)

Molecular Interactions of Arterial Hypertension in Its Target Organs
por: Kućmierz, Joanna, et al.
Publicado: (2021)

Arterial Hypertension—Oxidative Stress and Inflammation
por: Krzemińska, Julia, et al.
Publicado: (2022)

What Is the Role of Gut Microbiota in Obesity Prevalence? A Few Words about Gut Microbiota and Its Association with Obesity and Related Diseases
por: Tokarek, Julita, et al.
Publicado: (2021)

Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19
por: Młynarska, Ewelina, et al.
Publicado: (2022)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management
por: Kowalska, Klaudia, et al.
Publicado: (2022)

New Insights into Molecular Mechanisms of Chronic Kidney Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes
por: Tokarek, Julita, et al.
Publicado: (2023)

New Insights into the Use of Empagliflozin—A Comprehensive Review
por: Forycka, Joanna, et al.
Publicado: (2022)

Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure
por: Tokarek, Julita, et al.
Publicado: (2023)

The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder
por: Młynarska, Ewelina, et al.
Publicado: (2022)

Pharmacogenomics of Hypertension Treatment
por: Rysz, Jacek, et al.
Publicado: (2020)

Pharmacogenetics of Drugs Used in the Treatment of Cancers
por: Franczyk, Beata, et al.
Publicado: (2022)

Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients
por: Gluba-Brzózka, Anna, et al.
Publicado: (2018)

Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease
por: Bartnicki, Piotr, et al.
Publicado: (2016)

Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
por: Franczyk, Beata, et al.
Publicado: (2022)

The Effect of Diet on the Survival of Patients with Chronic Kidney Disease
por: Rysz, Jacek, et al.
Publicado: (2017)

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease
por: Rysz, Jacek, et al.
Publicado: (2020)

Ageing, Age-Related Cardiovascular Risk and the Beneficial Role of Natural Components Intake
por: Rysz, Jacek, et al.
Publicado: (2021)

Are Alterations in DNA Methylation Related to CKD Development?
por: Rysz, Jacek, et al.
Publicado: (2022)

The Role of Inflammation and Oxidative Stress in Rheumatic Heart Disease
por: Franczyk, Beata, et al.
Publicado: (2022)

Vegetarian Diet in Chronic Kidney Disease—A Friend or Foe
por: Gluba-Brzózka, Anna, et al.
Publicado: (2017)

Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients
por: Gluba-Brzozka, Anna, et al.
Publicado: (2019)

Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
por: Gluba-Brzózka, Anna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pvr8bibr7718vp2j7qlbkaclu5